CHK2 has also been noted to demonstrate cross-talk with ERK1/2 in DLBCL, with synergistic cytotoxicity of combined ERK and CHK2 inhibition in DLBCL cell lines, primary samples and in vivo models suggesting strong potential for clinical translation (92). The gene discussed is MAPK3; the disease is diffuse large B-cell lymphoma.